Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Transplant Immunology|January 20, 2022
Nanobody-based anti-CD22-chimeric antigen receptor T cell immunotherapy exhibits improved remission against B-cell acute lymphoblastic leukemiaTingting Zhang, Tian Wang, Fengtao You, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 15, 2025
Clinical efficacy and psychological benefits of ultrasound-guided vacuum-assisted excision in outpatient management of benign breast lesionsSiyuan Wang, Huan Zhang, Jing Lin, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|April 7, 2017
The effects and mechanisms of SLC34A2 on maintaining stem cell-like phenotypes in CD147+ breast cancer stem cellsYonggang Lv, Ting Wang, Jing Fan, et al.
Experimental Hematology & Oncology|September 29, 2022
CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemiaXuanqi Cao, Haiping Dai, Qingya Cui, et al.
Cancer Research|September 6, 2024
B7-H3-Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid TumorsLicui Jiang, Fengtao You, Hai Wu, et al.
Oncotarget|April 16, 2016
Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cellsJinle Tang, Jialu Li, Xuejun Zhu, et al.
Nano Letters|February 14, 2025
Boosting Tin Perovskite Solar Cell Performance via Light-Induced Interface DopingMulin Sun, Zhenzhu Zhao, Hao Xu, et al.
Science China. Life Sciences|March 11, 2016
Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cellsFengtao You, Licui Jiang, Bozhen Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2022
Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/LymphomaMingzhi Zhang, Dan Chen, Xiaorui Fu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2026
Allogeneic B7-H3-targeted CAR-Vδ1T cell therapy in advanced solid tumors: A phase I studyChang Liu, Jiarui Li, Dan Liu, et al.
Pageof 4